[go: up one dir, main page]

SG11201607465UA - Chromene and 1,1 a,2,7b-tetrahydrocyclopropa[c]chromene pyridopyrazinediones as gamma-secretase modulators - Google Patents

Chromene and 1,1 a,2,7b-tetrahydrocyclopropa[c]chromene pyridopyrazinediones as gamma-secretase modulators

Info

Publication number
SG11201607465UA
SG11201607465UA SG11201607465UA SG11201607465UA SG11201607465UA SG 11201607465U A SG11201607465U A SG 11201607465UA SG 11201607465U A SG11201607465U A SG 11201607465UA SG 11201607465U A SG11201607465U A SG 11201607465UA SG 11201607465U A SG11201607465U A SG 11201607465UA
Authority
SG
Singapore
Prior art keywords
chromene
pyridopyrazinediones
tetrahydrocyclopropa
gamma
secretase modulators
Prior art date
Application number
SG11201607465UA
Other languages
English (en)
Inventor
Ende Christopher William Am
John Michael Humphrey
Douglas Scott Johnson
Gregory Wayne Kauffman
Martin Youngjin Pettersson
Danica Antonia Rankic
Antonia Friederike Stepan
Patrick Robert Verhoest
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52815058&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201607465U(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of SG11201607465UA publication Critical patent/SG11201607465UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SG11201607465UA 2014-04-01 2015-03-18 Chromene and 1,1 a,2,7b-tetrahydrocyclopropa[c]chromene pyridopyrazinediones as gamma-secretase modulators SG11201607465UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461973436P 2014-04-01 2014-04-01
PCT/IB2015/051988 WO2015150957A1 (fr) 2014-04-01 2015-03-18 Chromène et 1,1a,2,7b-tétrahydrocyclopropa[c]chromène pyridopyrazinediones comme modulateurs de gamma-sécrétase

Publications (1)

Publication Number Publication Date
SG11201607465UA true SG11201607465UA (en) 2016-10-28

Family

ID=52815058

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201607465UA SG11201607465UA (en) 2014-04-01 2015-03-18 Chromene and 1,1 a,2,7b-tetrahydrocyclopropa[c]chromene pyridopyrazinediones as gamma-secretase modulators

Country Status (29)

Country Link
US (2) US20150274721A1 (fr)
EP (1) EP3126361B1 (fr)
JP (1) JP6643247B2 (fr)
KR (1) KR101886945B1 (fr)
CN (1) CN106211770B (fr)
AP (1) AP2016009465A0 (fr)
AR (1) AR099874A1 (fr)
AU (1) AU2015242330B2 (fr)
BR (1) BR112016022519A8 (fr)
CA (1) CA2944308A1 (fr)
CL (1) CL2016002422A1 (fr)
CR (1) CR20160454A (fr)
CU (1) CU20160140A7 (fr)
DK (1) DK3126361T3 (fr)
DO (1) DOP2016000266A (fr)
EA (1) EA031419B1 (fr)
EC (1) ECSP16078289A (fr)
ES (1) ES2759277T3 (fr)
IL (1) IL248154B (fr)
MD (1) MD20160102A2 (fr)
MX (1) MX369074B (fr)
NI (1) NI201600149A (fr)
PE (1) PE20161364A1 (fr)
PH (1) PH12016501864A1 (fr)
SG (1) SG11201607465UA (fr)
TW (1) TWI568733B (fr)
UY (1) UY36054A (fr)
WO (1) WO2015150957A1 (fr)
ZA (1) ZA201606252B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
EP3253755B1 (fr) * 2015-02-03 2020-08-26 Pfizer Inc Nouveaux pyridopyrazinediones cyclopropabenzofuranyl
CN106580997B (zh) * 2016-12-09 2018-01-19 张田 一种治疗先兆流产的药物组合物
CA3047096A1 (fr) 2016-12-16 2018-06-21 Pipeline Therapeutics, Inc. Methodes de traitement de la synaptopathie cochleaire
WO2020053654A1 (fr) * 2018-09-12 2020-03-19 Novartis Ag Composés antiviraux de pyridopyrazinedione
CN110907542A (zh) * 2018-09-17 2020-03-24 复旦大学 一种液质联用检测唾液中司来吉兰及其代谢物的方法
WO2020087031A1 (fr) 2018-10-26 2020-04-30 The Research Foundation For The State University Of New York Combinaison d'un inhibiteur de réabsorption spécifique de la sérotonine et d'un agoniste partiel du récepteur de la sérotonine 1a pour réduire la dyskinésie induite par l-dopa
CN113543852A (zh) 2019-03-06 2021-10-22 第一三共株式会社 吡咯并吡唑衍生物
CA3155287A1 (fr) 2019-09-26 2021-04-01 Novartis Ag Composes antiviraux de pyrazolopyridinone
IL319392A (en) 2022-10-18 2025-05-01 Pfizer Pectin-like phospholipase domain-containing protein 3 (PNPLA3) modification preparations
EP4604955A1 (fr) 2022-10-18 2025-08-27 Pfizer Inc. Utilisation de composés de protéine 3 contenant un domaine phospholipase de type patatine

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE239797T1 (de) 1993-01-25 2003-05-15 Takeda Chemical Industries Ltd Antikörper gegen beta-amyloid oder derivative davon und seine verwendung
DE19709877A1 (de) 1997-03-11 1998-09-17 Bayer Ag 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate
US8173127B2 (en) 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
WO1998044955A1 (fr) 1997-04-09 1998-10-15 Mindset Ltd. Anticorps recombines specifiques contre les terminaisons beta-amyloide, codage par molecule d'adn, et leurs procedes d'utilisation
GB9722520D0 (en) 1997-10-24 1997-12-24 Pfizer Ltd Compounds
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6743427B1 (en) 1997-12-02 2004-06-01 Neuralab Limited Prevention and treatment of amyloidogenic disease
WO2001062801A2 (fr) 2000-02-24 2001-08-30 Washington University Anticorps humanises sequestrant un peptide a$g(b)
DE10045112A1 (de) 2000-09-11 2002-03-21 Merck Patent Gmbh Verwendung von Indolderivaten zur Behandlung von Erkrankungen des zentralen Nervensystems
AU3976402A (en) 2000-11-03 2002-06-03 Proteotech Inc Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from uncaria tomentosa and related plants
EP1432444A4 (fr) 2001-08-17 2005-11-02 Lilly Co Eli Anticorps anti-a beta
US20030195205A1 (en) 2001-11-02 2003-10-16 Pfizer Inc. PDE9 inhibitors for treating cardiovascular disorders
DK1480983T3 (da) * 2002-02-28 2006-03-27 Sanofi Aventis Heteroarylsubstituerede 2-pyridinyl- og 2-pyrimidinyl- 6,7,8,9-tetrahydropyrimido[1,2a]pyrimidin-4-onderivater
DE10238723A1 (de) 2002-08-23 2004-03-11 Bayer Ag Phenyl-substituierte Pyrazolyprimidine
DE10238724A1 (de) 2002-08-23 2004-03-04 Bayer Ag Alkyl-substituierte Pyrazolpyrimidine
CA2501945A1 (fr) 2002-10-09 2004-04-22 Rinat Neuroscience Corp. Methodes de traitement de la maladie d'alzheimer au moyen d'anticorps diriges contre le peptide beta-amyloide et compositions les comprenant
US20040220186A1 (en) 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
WO2004110996A1 (fr) 2003-06-19 2004-12-23 Pfizer Products Inc. Antagoniste de nk1
WO2005025616A1 (fr) 2003-09-09 2005-03-24 Takeda Pharmaceutical Company Limited Utilisation d'un anticorps
GB0327319D0 (en) 2003-11-24 2003-12-24 Pfizer Ltd Novel pharmaceuticals
EP1720847A1 (fr) 2004-02-02 2006-11-15 Pfizer Products Incorporated Modulateurs du recepteur de l'histamine-3
US7456164B2 (en) 2004-05-07 2008-11-25 Pfizer, Inc 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
EP1595881A1 (fr) 2004-05-12 2005-11-16 Pfizer Limited Dérivés de tetrahydronaphthyridine en tant que ligands de récepteur H3 d'histamine
CA2575663C (fr) 2004-07-30 2013-04-23 Rinat Neuroscience Corp. Anticorps anti peptide amyloide beta, et leurs procedes d'utilisation
GB0423356D0 (en) 2004-10-21 2004-11-24 Merck Sharp & Dohme Therapeutic agents
WO2006069081A2 (fr) 2004-12-22 2006-06-29 Washington University In St. Louis Utilisation d'anticorps anti-a$g(b) pour le traitement d'un traumatisme cerebral
UY29504A1 (es) 2005-04-29 2006-10-31 Rinat Neuroscience Corp Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos.
NZ564187A (en) 2005-05-12 2010-03-26 Pfizer Anhydrous crystalline forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide
CA2603830A1 (fr) 2005-05-24 2006-11-30 Pharmacia & Upjohn Co Llc Pyridine [2,3-b] pyrazinones
WO2006126083A1 (fr) 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Composes de pyridine [3 , 4-b] pyrazinones utilises comme inhibiteurs de pde-5
WO2006126082A2 (fr) 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridine [3,4-b] pyrazinones
EP1899296B1 (fr) 2005-06-22 2010-11-17 Pfizer Products Inc. Antagonistes du recepteur 3 de l'histamine
US8158673B2 (en) 2005-10-27 2012-04-17 Pfizer Inc. Histamine-3 receptor antagonists
JP2009514846A (ja) 2005-11-04 2009-04-09 ファイザー・リミテッド テトラヒドロナフチリジン誘導体
WO2007063385A2 (fr) 2005-12-01 2007-06-07 Pfizer Products Inc. Antagonistes des recepteurs de l'histamine 3 pour des amines spirocycliques
WO2007069053A1 (fr) 2005-12-14 2007-06-21 Pfizer Products Inc. Antagonistes benzimidazoliques du récepteur h-3
WO2007088450A2 (fr) 2006-02-01 2007-08-09 Pfizer Products Inc. Chromane antagoniste du récepteur h-3
WO2007088462A1 (fr) 2006-02-01 2007-08-09 Pfizer Products Inc. Antagonistes du récepteur du h-3 à base de spirochromane
WO2007099423A1 (fr) 2006-03-02 2007-09-07 Pfizer Products Inc. Dérivés de 1-pyrrolidine indane en tant qu'antagonistes du récepteur d'histamine 3
JP2009539762A (ja) 2006-03-13 2009-11-19 ファイザー・プロダクツ・インク Ｈ３受容体のテトラリン拮抗薬
HRP20110539T1 (hr) 2006-04-21 2011-08-31 Pfizer Products Inc. PIRIDINO[3,4-b]PIRAZINONI
WO2007138431A2 (fr) 2006-05-30 2007-12-06 Pfizer Products Inc. Antagonistes de l'éther histamine-3 azabicyclique
BRPI0806473A2 (pt) 2007-01-22 2011-09-27 Pfizer Prod Inc sal de tosilato de um composto terapêutico e composições farmacêuticas do mesmo
AU2009307892A1 (en) * 2008-10-23 2010-04-29 Merck Sharp & Dohme Corp. Fused heterocyclic M1 receptor positive allosteric modulators
WO2012131539A1 (fr) 2011-03-31 2012-10-04 Pfizer Inc. Nouvelles pyridones bicycliques
SG11201407051XA (en) * 2012-05-16 2014-11-27 Janssen Pharmaceuticals Inc Substituted 3, 4 - dihydro - 2h - pyrido [1, 2 -a] pyrazine - 1, 6 - dione derivatives useful for the treatment of (inter alia) alzheimer's disease
UA110688C2 (uk) * 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
EP2945944B1 (fr) * 2013-01-17 2016-11-09 Janssen Pharmaceutica, N.V. Nouveaux dérivés de pyrido-pipérazinone substitués en tant que modulateurs de la gamma sécrétase
WO2015049616A1 (fr) * 2013-10-04 2015-04-09 Pfizer Inc. Nouvelles pyridinones bicycliques utilisées comme modulateurs de gamma-sécrétase

Also Published As

Publication number Publication date
CN106211770B (zh) 2018-02-06
MX2016012904A (es) 2016-12-07
CA2944308A1 (fr) 2015-10-08
CU20160140A7 (es) 2017-02-02
EP3126361A1 (fr) 2017-02-08
JP2017512803A (ja) 2017-05-25
ECSP16078289A (es) 2017-02-24
AU2015242330B2 (en) 2017-08-17
AU2015242330A1 (en) 2016-09-22
MD20160102A2 (ro) 2017-04-30
WO2015150957A1 (fr) 2015-10-08
JP6643247B2 (ja) 2020-02-12
UY36054A (es) 2015-10-30
US20170166566A1 (en) 2017-06-15
EP3126361B1 (fr) 2019-11-06
IL248154A0 (en) 2016-11-30
EA201600619A1 (ru) 2017-03-31
TW201540716A (zh) 2015-11-01
MX369074B (es) 2019-10-28
CN106211770A (zh) 2016-12-07
CR20160454A (es) 2016-12-06
KR20160137635A (ko) 2016-11-30
NI201600149A (es) 2016-11-18
HK1231481A1 (zh) 2017-12-22
US20150274721A1 (en) 2015-10-01
TWI568733B (zh) 2017-02-01
CL2016002422A1 (es) 2017-02-03
EA031419B1 (ru) 2018-12-28
IL248154B (en) 2020-09-30
PE20161364A1 (es) 2016-12-25
DK3126361T3 (da) 2020-01-02
ZA201606252B (en) 2018-05-30
AR099874A1 (es) 2016-08-24
DOP2016000266A (es) 2016-11-15
PH12016501864A1 (en) 2016-12-19
AP2016009465A0 (en) 2016-09-30
ES2759277T3 (es) 2020-05-08
BR112016022519A2 (pt) 2017-08-15
KR101886945B1 (ko) 2018-08-08
BR112016022519A8 (pt) 2018-03-06

Similar Documents

Publication Publication Date Title
IL248154B (en) Derivatives of chromane and 7b, 2, 1a, 1-tetrahydrocycloprop-c-chromane pyridopyrazinedione and their use for gamma-secretase modulation
EP3180067A4 (fr) Capuchons désinfectants
EP3212021A4 (fr) Casque à rotation dans le moule
IL247847A0 (en) ror gamma modulator and their use
EP3206696A4 (fr) Sharn multiplexés et leurs utilisations
EP3144243A4 (fr) Capuchon
PT3397702T (pt) Tinta piezorresistiva, métodos e utilizações da mesma
ZA201702720B (en) 1-alkyl-6-oxo-1,6-dihydropyridin-3-yl compounds and use as sgrm modulators
EP3128038A4 (fr) Matériau d'acier d'estampage à chaud
EP3212633A4 (fr) Puissants modulateurs de la sécrétase gamma
EP3166945A4 (fr) Nouveaux dérivés triazolopyrimidinone ou triazolopyridinone et leur utilisation
EP3134310A4 (fr) Unité de chenille et machine forestière
GB201421408D0 (en) An agrochemical composition, a method of preparing the same and the use thereof
EP3094798A4 (fr) Élément de retenue de barillet de cadenas
GB2537106B (en) A novel form of rimsulfuron, a process for its preparation and use of the same
EP3194628A4 (fr) Composés antisens et leurs utilisations
EP3176124A4 (fr) Grue
HUE039262T2 (hu) 5-oxa-2-azabiciklo [2.2.2] oktán-4-il- és 5-oxa-2-azabiciklo [2.2.1] heptán-4-il-származékok TAAR1 modulátorokként
ZA201803520B (en) Indane derivatives as mglur7 modulators
EP3194591A4 (fr) Composés antisens et leurs utilisations
EP3101644A4 (fr) Modèle de cavité de pulpe dentaire
PL3122184T3 (pl) Mikrokapsułki chlomazonu, ich wytwarzanie i zastosowanie
PL3105243T3 (pl) Pochodne 2',3'-dideoksy-5-fluorourydyny, sposób ich wytwarzania i zastosowanie
HK40112156A (zh) 药物、用途以及方法
EP3166946A4 (fr) Nouveaux dérivés imidazotriazinone ou imidazopyrazinone et leur utilisation